2 Stocks I'm Buying In June 2026
2 extracted signals · 1 resolved · 1 still active
The Patient InvestorIndependent analyst profile- Source published
- 25 Jun 2026, 17:40 UTC
- Recorded by Tahlil Plus
- 25 Jun 2026, 18:13 UTC
AI-generated source summary
The video analyzes two stocks, GFL and RGLD, with a focus on their financial metrics and market outlook. For GFL, the analysis highlights strong revenue and EBITDA growth, projected at 17.8% and 38.2% CAGR respectively, with free cash flow also showing significant growth. The stock's valuation is discussed in comparison to peers, indicating a potential discount. The analyst believes GFL's business model, with its recession-resistant and inflation-hedging characteristics, makes it an attractive investment. The target for GFL is set at around $45, with a potential failure bound if the price drops below $35. For Royal Gold (RGLD), the analysis emphasizes its royalty-based business model, which generates revenue from gold, silver, and copper production. The company has a strong global portfolio of mining assets, with a significant portion in tier-one jurisdictions, and a longer mine life compared to peers. The analyst projects the stock to reach $217, with a failure bound below $195, citing its favorable cost structure and inflation-resilient business model as key drivers.
AI-generated summary based on the source content.
Signal outcomes at a glance
Partially ResolvedSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Live evaluation in progress
1 signal remains active.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.